Compare Garmin Ltd. (GRMN) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Medpace Holdings Inc — how do they compare? Garmin Ltd. trades at $270.51 (market cap $51.77B), while Medpace Holdings Inc trades at $615.1 (market cap $16.82B). The key difference: Garmin Ltd. is far larger — about 3.1× Medpace Holdings Inc's market cap, and Garmin Ltd. pays a 1.56% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and Medpace Holdings Inc for 14 Days on average.
| GRMN | MEDP | |
|---|---|---|
Market Cap | $51.77B | $16.82B |
Volume | 961,398 | 223,093 |
Sector | Technology | Health |
52-Week High | $313.16 | $630.19 |
52-Week Low | $187.10 | $393.42 |
Typical Hold Time | 83 Days | 14 Days |
Enterprise Value | $49.28B | $16.44B |
Dividend Yield | 1.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $276.16, down 1.09% on the day, with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, revenue growth from $4.9B in 2022 to $7.25B in 2025, and robust profitability margins. Recent news highlights product innovation and industry awards, reinforcing its market position.
The outlook is supported by solid financial health and analyst consensus pointing to upside, but risks include competitive pressures and market volatility. The stock presents a growth opportunity driven by execution, though investor caution is warranted near-term given technical weakness and macroeconomic uncertainties.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
